It was found that AS1842856 inhibits the GSK3α/β to suppress tauopathy by accelerating GSK3α/β exocytosis in cultured neural cells (He et al., 2025), whereas the in vivo studies of the inhibitor in the context of a neurological disorder are still lacking. This evidence concerns the gene GSK3A and nervous system disorder.